The investigators aimed to prospectively investigate the effects of esomeprazole on glycaemic
control in patients with type 2 diabetes mellitus. The investigators also aimed to associate
this effect with gastrin levels. Thirty-two type 2 diabetes mellitus objects were recruited
into intervention (n=16) and control (n=16) groups. The participants in the intervention
group were prescribed 40 mg of esomeprazole treatment for three months. At the beginning of
the study and at month 3, HbA1c level (%) and gastrin levels (pmol/L) of participants were
assessed. Then the baseline and 3rd month data of groups were compared.